Oxford Nanopore Technologies PLC (4R0) Stock Price & Analysis
4R0 Stock Chart & Stats
- Day’s Range
- EUR 2.73 - EUR 2.80
- 52-Week Range
- EUR 1.16 - EUR 2.89
- Previous Close
- EUR 2.82
- Volume
- 200
- Average Volume (3M)
- 1,315
- Market Cap
- EUR 2.60B
- Enterprise Value
- EUR 1.06B
- Total Cash (Recent Filing)
- EUR 184.80M
- Total Debt (Recent Filing)
- EUR 41.80M
- Price to Earnings (P/E)
- ―
- Beta
- 0.65
- Next Earnings
- Mar 09, 2027 (Est.)
- EPS Estimate
- -0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin
The sharp 2025 revenue rebound indicates improving commercial traction after weakness in 2023 and near-flat growth in 2024. Combined with a higher gross margin, this suggests stronger customer adoption and product mix, creating a better foundation for operating leverage as scale increases.
Recurring Consumables Model
ONT’s instrument-and-consumables model can build recurring revenue as customers run more samples on an installed platform. Repeat purchases of flow cells and related products may deepen customer relationships, support revenue visibility, and increase the lifetime value of each instrument placement.
Low Financial Leverage
Very low leverage limits the immediate pressure from debt servicing and reduces balance-sheet risk relative to a highly indebted business. This provides greater financial flexibility to support product development and commercial expansion, although it does not remove the need to improve profitability and cash generation.
Bears Say
Persistent Losses
Deeply negative net and EBIT margins show that the current cost base remains too high relative to revenue, despite the latest growth rebound. Continued losses could delay sustainable profitability, constrain reinvestment capacity, and make future performance dependent on achieving substantial operating leverage.
Negative Cash Generation
Persistent negative operating and free cash flow means the business is not yet funding operations internally. Even though cash burn improved from 2024 on an absolute basis, ongoing outflows can reduce financial flexibility and increase reliance on external funding while losses continue.
Eroding Equity Base
The fall in shareholder equity reflects the cumulative effect of ongoing losses and reduces the capital cushion available to absorb further underperformance. If losses persist, additional erosion could weaken long-term financial resilience and limit the resources available for growth investments.
Oxford Nanopore Technologies PLC News
4R0 FAQ
What was Oxford Nanopore Technologies PLC’s price range in the past 12 months?
What is Oxford Nanopore Technologies PLC’s market cap?
When is Oxford Nanopore Technologies PLC’s upcoming earnings report date?
How were Oxford Nanopore Technologies PLC’s earnings last quarter?
Is Oxford Nanopore Technologies PLC overvalued?
Does Oxford Nanopore Technologies PLC pay dividends?
What is Oxford Nanopore Technologies PLC’s EPS estimate?
How many shares outstanding does Oxford Nanopore Technologies PLC have?
What happened to Oxford Nanopore Technologies PLC’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Oxford Nanopore Technologies PLC?
What is the TipRanks Smart Score and how is it calculated?
Oxford Nanopore Technologies PLC Stock Smart Score
Company Description
Oxford Nanopore Technologies PLC
Oxford Nanopore Technologies plc, founded in 2005 and originally known as Oxford NanoLabs Limited before its name change in May 2008, is a United Kingdom-based enterprise that specializes in developing and commercializing an innovative system for analyzing diverse molecular structures through nanopore-based sensing. Its product range features a variety of devices, including the portable MinION for sequencing deoxyribonucleic acid and ribonucleic acid, and the MinION Mk1C, which integrates basecalling, data analysis, touchscreen controls, and wireless connectivity. For benchtop operations, the company offers the GridION, capable of running and analyzing up to five MinION or Flongle flow cells, as well as the GridION Mk1 nanopore sequencer. High-yield sequencing is made accessible with the PromethION 2 Solo and PromethION 2, while the PromethION 24 and PromethION 48 provide benchtop nanopore sequencers for multiple users to achieve multi-sample and multi-experiment results. Further complementing these devices are Flongle, an adapter for MinION or GridION units, and VolTRAX, a USB-powered tool designed to automate laboratory processes preceding nanopore sequencing. The company also provides a suite of software solutions: MinKNOW facilitates data acquisition, real-time analysis and feedback, local basecalling, and data streaming; specialized Basecalling tools pinpoint the identity and sequence of bases on DNA/RNA molecules; EPI2ME is a cloud-based platform for comprehensive, real-time analysis of nanopore data; and EPI2ME Labs offers bioinformatics support to help users refine their skills and confidence in analyzing their sequencing data. Additionally, Oxford Nanopore Technologies is actively developing new products such as MinION Mk1D, Ubi, Plongle, and SmidgION. All of its products are available for purchase online.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Francis Albert Luc Van Parys
- Employees
- 1,314
- Website
- nanoporetech.com
- Address
- Gosling Building, Oxford, OX, OX4 4DQ, GB
Oxford Nanopore Technologies PLC (4R0) Earnings & Revenues
4R0 Earnings Call
Earnings Call SentimentPositive
The call presents a constructive operational and financial progression: strong top‑line growth (+24.2% constant currency), marked shift toward higher‑value applied markets (clinical +59%), meaningful margin improvements and a stronger cash position (GBP 302.8m). Management has executed strategic reprioritization and cost discipline, delivering a 26% improvement in adjusted EBITDA and guiding to FY26 growth (21–25% ccy) and FY26 gross margin expansion (62%). Key negatives are ongoing adjusted EBITDA and cash losses (with breakeven targeted in 2027/2028), one‑off margin hits (obsolete inventory and FX), restructuring costs, product discontinuations/pauses (P2 Solo, ElysION), delays to some product launches (PromethION timing) and market‑specific headwinds (China/APAC export controls). Overall, positives—broad growth, margin momentum, cash runway, and clearer strategic focus—outweigh the remaining execution and market risks, with management articulating a credible path to profitability.
View all DE:4R0 earnings summaries4R0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 4 | 3 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 12 | 0 | 0 |